Investor Presentation First Nine Months of 2022
104
Investor presentation
First nine months of 2022
Novo NordiskⓇ
There is broad potential for cell therapies and Novo Nordisk has
capabilities to explore the potential
Broad potential for clinical use of cell therapies
Parkinson's disease
Stroke
Alzheimer's disease
Dry AMD
Blindness
Hearing loss
Congenital bone disorders
Chronic heart failure
Spinal cord injury
Chronic kidney disease
NASH
Diabetes
Osteoarthritis
Muscular dystrophy
Multiple sites: Cancers and wound healing
Maturing the platform to enable development of
competitive cell therapies
Novo Nordisk capabilities
In-depth know-how on
Focus area
Pluripotent stem cell
embryonic pluripotent stem cells
undifferentiated stem
Exploitation of quality controlled
stem cells
Bank of several
cells
Differentiated to
specific cell types
Upscaling, manufacturing
and delivery/devices
Clinical development and
regulatory affairs
IP-protected protocols for
differentiation
GMP-grade cell manufacturing
and development of cell delivery
devices¹
Early interactions with regulators
Clinical trial experience
1In collaboration with academia and industrial partners
Dry AMD: Dry age-related macular degeneration; NASH: Non-alcoholic steatohepatitis; IP: Intellectual property; GMP: Good manufacturing practicesView entire presentation